Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab SC vs IV in Advanced Nasopharyngeal Carcinoma
NCT05751486Phase 1Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Nov 2022
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of toripalimab in nasopharyngeal carcinoma (NPC) (4 arms), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration at 2 years, Time to Maximum Plasma Concentration at 2 years and 5 more. Started Nov 2022; status: completed.
02
Drugs
toripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05751486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05751486.